Kanwa Holdings LP, an affiliate of Barings, has acquired Midatech Pharma US, a specialty pharmaceutical company focused on products that help patients treat cancer. The seller was Midatech Pharma Plc. No financial terms were disclosed.
CHARLOTTE, N.C., Nov. 13, 2018 /PRNewswire/ — Barings Alternative Investments, part of Barings LLC (“Barings”), one of the world’s leading financial services firms, announced today that Kanwa Holdings, LP, an investment vehicle affiliated with Barings, completed the acquisition of Midatech Pharma US Inc. (“Midatech Pharma US”) from Midatech Pharma Plc.
Midatech Pharma US is a specialty pharmaceutical company focused on oncology supportive care, with five marketed products in their portfolio. These products help patients manage the impact of their cancer as well as the side effects of their cancer therapies. The company will continue to be based in Raleigh, North Carolina and intends to immediately expand its commercial presence in oncology practices and augment its product portfolio with additional therapeutics.
“We are excited to close the acquisition of the Midatech Pharma US supportive care business. We look forward to expanding patient access and increasing the breadth of therapeutic options available to cancer patients who experience significant adverse effects and quality-of-life issues associated with cancer treatments. This transaction aligns with our focus on the specialty pharmaceutical healthcare sector within our Private Equity and Real Assets platform,” said Jon Rotolo, Head of the Barings Private Equity and Real Assets team.
Kanwa Holdings, LP is a limited partnership owned by funds managed by or through Barings LLC.
McGuireWoods LLP served as Barings’ legal advisor on the transaction.
Barings Alternative Investments (“BAI”), part of Barings LLC, is a 470+ associate team located across 11 countries that manages $49.3 billion* in client capital. BAI seeks differentiated sources of returns by incorporating decades of investment experience in alternative assets offering investors access to a diverse range of opportunities across private equity, real assets, asset-based investments and the four quadrants of real estate. We serve as a trusted partner to clients, leveraging our global presence and robust origination capabilities to identify the most attractive risk-adjusted return opportunities. The Barings Private Equity and Real Assets team focuses on control positions in actively-managed, thematically-driven asset-based investments that generate both current income and opportunity for capital appreciation. Led by a research intensive investment process that identifies long-term investment trends, the team invests across multiple sectors in three asset classes: Infrastructure, Intangible Assets and Natural Resources.
Barings is a $310+ billion* global financial services firm dedicated to meeting the evolving investment and capital needs of our clients. We build lasting partnerships that leverage our distinctive expertise across traditional and alternative asset classes to deliver innovative solutions and exceptional service. Part of MassMutual, Barings maintains a strong global presence with over 1,900 professionals and offices in 16 countries. Learn more at www.barings.com.
*As of September 30, 2018